1. Introduction {#s0005}
===============

Hydrogen sulfide (H~2~S); a toxic gas, is endogenously produced, bioactive, and contributes to numerous physiological functions in mammalian systems. Studies support the possibility that H~2~S has therapeutic potential for treating multiple diseases including cardiovascular diseases. For example, experimental animal studies show that H~2~S may be effective in treating atherosclerosis and protecting against ischemia-reperfusion injury [@bib1; @bib2; @bib3]. Interest in the cytoprotective actions of H~2~S has grown since the discovery that it can induce a hypometabolic state characterized by decreased O~2~ consumption, heart rate, and body temperature in non-hibernating rodents [@bib4]. Although not discussed in this review, H~2~S-dependent hypometabolism is an O~2~-dependent phenomenon [@bib5]. The proposed mitochondrial and signaling actions of H~2~S make this molecule an attractive intervention for preventing and treating diseases and trauma-associated injuries. In this review article, we provide an overview of H~2~S redox biology as it relates to the biological and pharmacological actions of this interesting new signaling molecule in mammalian systems.

2. Historical benefits of H~2~S {#s0010}
===============================

The ancient Greeks, Egyptians, and Romans regularly bathed in natural sulfur springs as treatments for disease [@bib6]. Depending on the microbiota and oxygen content, sulfur springs typically contain H~2~S concentrations ranging from 1 to 500 μM [@bib7] with anti-inflammatory, anti-bacterial, vasodilatory, and anti-fungal properties attributed to the sulfur-containing water [@bib8]. Epidemiological studies report that a diet rich in organosulfur species is associated with longevity and decreased morbidity [@bib9]. Members of the *Allium* genus (garlic and onions), which contain organosulfur compounds have a well-documented history of health benefits [@bib10]. Indeed, garlic-derived compounds such as diallyl trisulfide release H~2~S in the presence of cellular reductants like glutathione (GSH) [@bib11]. Populations that consume garlic regularly have low blood pressure, low cholesterol, and less vascular disease [@bib12]. While administration of exogenous sulfur-containing compounds shows strong promise as therapies, H~2~S is also endogenously produced in many different human tissues.

3. Endogenous production of H~2~S {#s0015}
=================================

In the early 1990s, it was discovered that H~2~S is enzymatically produced by two cytosolic enzymes; cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL) [@bib13; @bib14]. Seminal work of Abe and Kimura showed, for the first time, that H~2~S enhances long-term potentiation in the hippocampus [@bib15]. Specifically, they demonstrated that H~2~S was produced by CBS and that exogenous H~2~S enhanced NMDA receptor-mediated responses. Since then many studies have shown that CBS and CGL are expressed in human tissues with H~2~S contributing to physiological and pathophysiological processes ([Table 1](#t0005){ref-type="table"}). In addition to CBS and CGL, there are other enzymes that produce H~2~S with several utilizing cysteine as a substrate. The enzyme 3-mercaptopyruvate S-transferase (3-MST) is found in mitochondria and cytosol and produces H2S [@bib16]. Several H2S producing enzymes are pyridoxal-5′-phosphate (PLP) dependent enzymes [@bib17]. Moreover, other sulfur-containing amino acids, such as cystine and homocysteine, can be metabolized to generate H~2~S. The enzymatic mechanisms of H~2~S production are shown in [Fig. 1](#f0005){ref-type="fig"}. Many of these enzymes participate in the cellular sulfur cycle and have multiple enzymatic activities, including H~2~S generation. Because the concentration of reduced sulfur species has an effect on many cellular processes [@bib18], the activity of these enzymes is tightly regulated. Much of this regulation is linked to substrate availability [@bib19]. Moreover, these are redox-sensitive enzymes, which exhibit increased activity under oxidative conditions [@bib20]. Considering that H~2~S; a reductant, is a product of these enzymes, it is conceivable that enzymatic activity may also be subject to negative feedback regulation. Finally, work by Wang et al. suggests that under certain conditions, such as oxidative stress, H~2~S-producing enzymes translocate from the cytosol to mitochondria [@bib21]. This dynamic regulation bolsters the argument that H~2~S may function as a redox signaling molecule.

4. Catabolism of H~2~S {#s0020}
======================

Several regulated and unregulated non-enzymatic processes participate in H~2~S catabolism. These pathways maintain *in vivo* H~2~S concentrations, most likely, in the nM to low μM range. H~2~S can react with heme proteins in mitochondria and therefore H~2~S can function as a mitochondrial respiratory toxicant [@bib22; @bib23]. Fatal industrial accidents have been documented in individuals exposed to high concentrations of H~2~S gas (e.g., \>1000 pm) [@bib24]. Therefore, the toxicological profile of H~2~S has been well-studied and documented [@bib24]. The mechanism of toxicity is through the binding of H~2~S to cytochrome *c* oxidase (CcO) mediating respiratory inhibition [@bib22]. However, this interaction is complex and poorly understood because H~2~S can act as both an inhibitor and an electron donor for CcO [@bib25]. H~2~S binds to the oxidized states of the heme *a*-*a*~*3*~ binuclear center, resulting in the reduction of the heme molecules [@bib26]. Excess H~2~S can also reduce Cu~B~ [@bib27]. While the stoichiometry may vary, Cooper and Brown reported that 3 molecules of H~2~S bind per inhibited CcO [@bib28]. In this inhibitory reaction, H~2~S is oxidized to sulfane sulfur and this is coupled to consumption of molecular O~2~ [@bib28]. Unlike nitric oxide (^•^NO), the inhibition of CcO by H~2~S is noncompetitive with O~2~ [@bib27; @bib29]. In addition, H~2~S can also directly reduce the electron carrier cytochrome *c* producing the one electron oxidation product, the thiyl radical (^•^SH) [@bib28].

Rhodanese, a mitochondrial sulfur transferase enzyme, catalyzes the oxidation of H~2~S [@bib30]. It is one part of three enzymatic activities characterized as a major pathway for H~2~S catabolism. This pathway consists of a sulfide quinone oxido-reductase (SQR), a sulfur dioxygenase, and the sulfur transferase enzyme rhodanese ([Figs. 2 and 3](#f0010 f0015){ref-type="fig"}). H~2~S reduces the external disulfide on the SQR to form a thiol (RSH) and a perthiol (RSSH). This two electron oxidation of H~2~S reduces the FAD prosthetic group, which uses ubiquinone (Q) as an electron acceptor [@bib31] The second sulfur atom on the perthiol is a reactive sulfane (S^0^), which is oxidized by a sulfur dioxygenase enzyme encoded by the gene *ETHE1*, consuming O~2~ and H~2~O to form sulfite (SO~3~^−2^). While the protein responsible for this enzymatic activity is not known, the *ETHE1* gene encoding the protein has been identified. Mutations in this gene cause a buildup of H~2~S leading to ethylmalonic encephalopathy [@bib32; @bib33]. Rhodanese then transfers a sulfane sulfur to sulfite to form thiosulfate (S~2~O~3~^−2^) [@bib34]. This proposed oxidation pathway, in close proximity to CcO, functions as a major clearance pathway of cellular H~2~S. H~2~S can also be oxidized by non-mitochondrial heme proteins such as hemoglobin (Hb) and myoglobin [@bib35]. H~2~S will reduce the ferric iron in met-Hb, restoring the oxygen binding abilities of the protein [@bib36]. At high concentrations of H~2~S, sulf-Hb can also be formed from oxy-Hb [@bib37]. While displaying very weak affinity for O~2~, sulf-Hb can still deliver O~2~, albeit with no cooperativity [@bib38]. As a result, the bioavailability of H~2~S, whether in the context of steady state *in vivo* concentrations or exogenously administered, is dictated by the O~2~ concentration. Therefore, O~2~ can be considered an H~2~S antagonist, accelerating its oxidation and attenuating its biological actions. The effect of O~2~ on H~2~S concentration is both direct and indirect. The spontaneous reaction of H~2~S with O~2~, while slow, can cause an appreciable decrease in the H~2~S concentration. Thus, tissues with relatively high O~2~ concentrations (e.g., alveolar epithelium) may have less H~2~S compared to tissues that are in a lower O~2~ environment (e.g., centrilobular region of liver). This has implications in pathological states of hypoxia such as ischemia-reperfusion, where the availability, and thus the signaling effects of H~2~S may be augmented. Furthermore, O~2~ concentration can indirectly affect H~2~S concentration through changes in the redox state of heme proteins. Proteins such as Hb will react with H~2~S at different rates depending on the redox status of the hemes. For example, H~2~S will react more rapidly with met-Hb (Fe^+3^) than with deoxy-Hb (Fe^+2^) [@bib36].

Because H~2~S is a nucleophile, it can also react with electrophilic lipids [@bib39]; and the thiolate anion, HS^−^, can also reduce disulfide bonds ([Fig. 2](#f0010){ref-type="fig"}) [@bib40]. Indeed, the exfoliation of skin cells in hot sulfur springs is due to H~2~S reducing the structural disulfide bonds of cellular junctions in keratinocytes [@bib8]. While this can be harmful at high concentrations, the reduction of external disulfide bonds by H~2~S may, in some instances, reverse a deleterious post-translational protein modification. Although still contentious, the *S*-sulfhydration of cysteine residues may represent an important sink for free H~2~S [@bib41]. In theory, H~2~S can also reduce higher thiol oxidation states such as *S*-nitrosothiols and sulfenic acids [@bib42]. H~2~S can also be methylated by the cytosolic enzyme thiol-*S*-methyltransferase to form methane thiol. As with virtually all molecules, H~2~S can react with other free radical species, as well as, a number of non-radical reactive oxygen (ROS) and nitrogen (RNS) species ([Fig. 2](#f0010){ref-type="fig"}) [@bib43]. Many of the oxidized sulfur species as well as sulfur-centered radicals formed are less reactive than their oxygen-containing counterparts [@bib44]. One of the most important oxidants responsible for the catabolism of H~2~S is O~2~. In the presence of molecular O~2~ and redox active metals, H~2~S will spontaneously oxidize [@bib45]. In an oxygenated biological medium, metalloproteins catalyze H~2~S oxidation. This makes O~2~ tension a critical methodological consideration when conducting biologically relevant experiments.

5. Measurement of H~2~S in mammalian samples {#s0025}
============================================

As the field of H~2~S continues to grow, accurate measurement of H~2~S in biological samples is critical for proper understanding of its biochemistry and identifying its key physiological roles. Early studies reported endogenous H~2~S concentrations in mammalian tissues to be approximately 160 μM [@bib46]. However, when considering that the *K*~*i*~ of CcO for H~2~S is 0.2 μM [@bib28] it is unlikely that free H~2~S exists at high μM concentrations. Older methods relied on inducing large pH shifts during sample preparation followed by capturing the released sulfide anions with metals such as silver or zinc [@bib47] and then measuring these complexes by spectrophotometry or chromatography [@bib46]. One problem with these methods is that they liberate multiple acid-labile sulfur species, including those in Fe--S centers, giving artificially high values. Recently, the mono-bromobimane assay has been refined to exclude sulfur species other than free H~2~S [@bib47]. As techniques improve, the reported concentrations of H~2~S in mammalian samples have decreased from the 100--200 μM range to less than 500 nM [@bib48]. Other techniques, including polarography, have measured H~2~S concentrations in mouse blood in the sub-μM range (Stein et al., unpublished data). These lower values are more plausible when considering the inhibitory potential of H~2~S for heme-containing proteins, in addition to, parallels between H~2~S and other signaling molecules such as ^•^NO and carbon monoxide (CO). It is also important to note that whole tissue or cell lysate measurements of H~2~S overlook compartmental differences in H~2~S concentrations and thus likely underestimate the effective localized concentrations of H~2~S *in vivo*. Because the technology required to accurately measure H~2~S on the sub-cellular level is unavailable, it is important to recognize these limitations when considering physiologically relevant levels and reactions of H~2~S.

6. Biological roles of H~2~S {#s0030}
============================

Like ^•^NO and CO, H~2~S is produced in many different cell types and can easily diffuse without the need for transporters. Therefore, it is not surprising that H~2~S has diverse biological actions ([Fig. 4](#f0020){ref-type="fig"}). Important factors that determine the biological actions of H~2~S include, but are not limited to, differences in the solubility of H~2~S in aqueous vs. lipid phases, proximity of the target to H~2~S-detoxifying enzymes, heme redox state, and inter- and intracellular differences in O~2~ tension.

7. Vasoactivity {#s0035}
===============

One of the first physiological roles that prompted investigators to regard H~2~S as the "third gaseous signaling molecule" was vasodilation. In 2001, Zhao et al. showed that H~2~S decreased blood pressure in rats *in vivo* and caused vascular smooth muscle cell (VSMC) relaxation *in vitro* [@bib49]. H~2~S-mediated vasodilation has also been shown in the ileum of the gastrointestinal tract and the *vas deferens* [@bib50]. Additionally, others have shown that transgenic mice deficient in CBS are chronically hypertensive [@bib51]. H~2~S is thought to induce vasodilation by increasing the conductance of adenosine triphosphate (ATP) sensitive potassium channels (*K*~ATP~). Furthermore, the specific molecular targets of H~2~S were shown to be cysteine 6 and 26 of the extracellular portion of the rvSUR1 subunit of the *K*~ATP~ channel complex [@bib52]. These vicinal thiols form a disulfide bond, which H~2~S reduces, increasing channel conductance. However, the vasodilatory effect of H~2~S is highly O~2~-dependent as supra-physiological levels of O~2~ (200 μM) cause H~2~S-induced vasoconstriction [@bib53]. Recently, conflicting reports have emerged showing that the contribution of the *K*~ATP~ channels to H~2~S-induced vasodilation is minimal and that vasodilation is due to metabolic inhibition (i.e., decrease in ATP), intracellular pH changes, and modulation of Cl^−^/HCO^−^~3~ channels [@bib54]. There are several methodological differences including O~2~ tension, pre-contraction agent, vessel type, and the type of sulfide-based chemical used, which may account for discrepancies among experimental studies. There are also indications that H~2~S may act through ^•^NO to stimulate vasodilation. Studies suggest that H~2~S liberates ^•^NO from *S*-nitrosothiols [@bib55]. Others show that endothelial denudation and nitric oxide synthase (NOS) inhibitors shift the dose--response curve to the right [@bib56]. However, H~2~S increases eNOS phosphorylation and subsequent ^•^NO production in an Akt-dependent manner [@bib57]. While the mechanism(s) responsible for vasodilation remain unclear, the role of H~2~S as a vasodilator is accepted and there is great interest in employing H~2~S-releasing agents as therapies to treat hypertension.

8. Angiogenesis {#s0040}
===============

H~2~S can cause cell proliferation and migration [@bib58; @bib59]; however, there appears to be a narrow concentration range of the proliferative effect, below which no effect is seen and above which there is anti-proliferation and H~2~S cytotoxicity [@bib60]. In cell culture experiments, low micromolar concentrations of H~2~S increase endothelial cell number, proto-vessel formation, and cell migration [@bib58]. Chicken chorioallantoic membranes, an *in vivo* model of angiogenesis, display increased branching and lengthening of blood vessels in response to 48 h incubation with H~2~S [@bib59]. Additionally, aortic tissue isolated from transgenic mice lacking CSE, the primary H~2~S-producing enzyme in the endothelium, exhibit marked decreases in angiogenesis [@bib59].

The mechanism of H~2~S-induced angiogenesis operates through several pathways, including activation of ATP-sensitive potassium (*K*~ATP~) channels [@bib49]. Papapetropoulos et al. showed that treatment of endothelial cells with the *K*~ATP~ channel inhibitor glibenclamide reduced cell migration, which was accompanied by decreased H~2~S-induced p38 and heat shock protein 27 (Hsp27) phosphorylation [@bib59]. Additionally, H~2~S can stimulate angiogenesis through phosphatidylinositol 3-kinase (PI3K) and Akt activation [@bib61]. H~2~S can also activate hypoxia inducible factor-1α (HIF-1α) and thus increase expression of vascular endothelial growth factor (VEGF) [@bib62]. Conversely, VEGF-stimulated angiogenesis is suppressed in CSE knockout mice [@bib58].

Endogenous H~2~S production is known to be upregulated during wound healing [@bib63]. Topically applied H~2~S accelerates wound closure and healing [@bib59]. Angiogenesis is very important in both acute and chronic ischemia as poorly vascularized tissue will lose function and possibly become necrotic. In models of chronic hind limb ischemia, sodium hydrosulfide (NaHS) increased capillary formation and blood flow [@bib64]. Similar results were found in chronically ischemic hearts with improvements in cardiac function following H~2~S treatment [@bib65]. These studies indicate that endogenous H~2~S is crucial in physiological angiogenesis and that those capabilities can be employed in disease treatment.

9. Inflammation {#s0045}
===============

Several studies report that H~2~S is a mediator of inflammation [@bib66; @bib67; @bib68; @bib69], while others report that H~2~S ameliorates inflammatory sequelae [@bib70; @bib71; @bib72]. These studies are likely in conflict because different models of inflammation, H~2~S production inhibitors, H~2~S "donors", and different O~2~ tensions were used for experiments. Using NaHS, several groups have shown that H~2~S augments neutrophil migration and adhesion, nociception, and increases endotoxemia [@bib66; @bib67; @bib73]. This is likely because upon application NaHS "releases" all its H~2~S instantly, which may be pro-inflammatory in some cases. This is in contrast to the much slower kinetics and magnitude of endogenous H~2~S production. Moreover, a burst of H~2~S may alter ^•^NO homeostasis as well, decreasing its bioavailability through direct reactions and through inhibition of NOS [@bib74]. Regarding endogenous production, some groups report that CSE is upregulated during lipopolysaccharide (LPS)-induced endotoxemia and that pharmacological inhibition of CSE attenuated inflammation [@bib68; @bib69]. Whiteman et al. highlighted differences between using rapid release of high concentrations of H~2~S vs. using slow-releasing donor compounds, which more closely mimic endogenous production. They showed that a slow-releasing H~2~S donor dose-dependently inhibited LPS-induced inflammation by decreasing the pro-inflammatory mediators IL-1β, IL-6, TNF-α, and PGE~2~ [@bib74]. Additionally, they showed an increase in the anti-inflammatory cytokine IL-10 in an NFκB-dependent mechanism [@bib75]. This report is similar to others that show H~2~S-dependent inhibition of ^•^NO and TNF-α through p38 inhibition; a known downstream target of H~2~S [@bib76]. In contrast to [@bib68], which used a non-specific PLP-dependent enzyme inhibitor, propargylglycine (PAG), others have used the CSE inhibitor β-cyanoalanine [@bib70]. Treatment with β-cyanoalanine increased leukocyte adhesion to the endothelium, indicating some off-target effects of PAG and that endogenous H~2~S is anti-inflammatory [@bib70]. Like vasodilation, the anti-inflammatory effects of H~2~S appear to be *K*~ATP~ channel-dependent with glibenclamide reversing the inhibitory effects of H~2~S on leukocyte adhesion [@bib71]. Although there are conflicting reports regarding the role of H~2~S in inflammation, common themes have emerged that shed light on the reasons for these disparate results. H~2~S donor compounds with slow release kinetics that mimic endogenous production appear to ameliorate inflammation. This is contrasted against the apparent pro-inflammatory potential of low purity sulfide salts, which immediately dissociate in solution to rapidly deliver large doses of H~2~S. As with vasoactivity, the role of H~2~S in inflammation is redox sensitive and this becomes important when impure sulfide salts are used in experiments. In addition to sulfide, these salts contain oxidized sulfur species such as sulfates, sulfenic acid, and sulfonates. In contrast to H~2~S, these species can have proinflammatory properties [@bib75]. Additionally, experiments conducted at supra-physiological O~2~ tensions may yield misleading results, as high O~2~ concentrations increase production of proinflammatory oxidized sulfur species [@bib53; @bib75]. In order to move H~2~S from the "bench to the bedside", comprehensive pharmacological studies are needed, which focus on routes of administration, type of donor compounds used, kinetics and magnitude of H~2~S release, timing of the intervention, physiologically and pathologically relevant O~2~ tensions, and the type of inflammatory condition being addressed.

10. Hydrogen sulfide and cytoprotection {#s0050}
=======================================

As mentioned in earlier sections, the therapeutic window for effective H~2~S treatment is likely very narrow because H~2~S is a potent inhibitor of mitochondrial respiration. Therefore, several pharmacological factors including dose, route of administration, and timing of H~2~S exposure must be carefully considered when using H~2~S as a therapy. In the following paragraphs, select examples from the literature are presented showing cytoprotective effects of H~2~S and other sulfide-based compounds in models of cardiovascular disease.

11. Cardiovascular disease {#s0055}
==========================

Studies show decreased plasma levels of H~2~S in atherosclerosis models [@bib51; @bib77]. Furthermore, endogenous production of H~2~S in sclerotic aortic tissues is impaired due to decreased expression of CGL in VSMCs [@bib78]. Conversely, in cases of H~2~S over-production (e.g., Trisomy 21) progression of atherosclerosis is slower [@bib79]. H~2~S may slow disease progression of atherosclerosis by inhibiting several elements of foam cell formation. Macrophages incubated with oxidized lipoprotein (oxLDL) show decreased intracellular lipid accumulation when treated with H~2~S, whereas inhibiting endogenous H~2~S production exacerbates lipid accumulation [@bib80]. Expression of scavenger receptors responsible for oxLDL accumulation was also decreased with H~2~S treatment [@bib80]. Using apolipoprotein E knockout mice, H~2~S decreases expression of adhesion molecules, thus preventing the recruitment of macrophages into the vascular intima, which is accompanied by a reduction in pro-inflammatory cytokines [@bib2]. In atherosclerotic plaques, VSMCs proliferate and assume a fibrogenic phenotype, contributing to vessel occlusion. H~2~S, at high concentrations, prevents VSMC proliferation [@bib81]. Together, these results support the concept that sulfide-based therapies attenuate some of the early metabolic changes that contribute to cardiovascular disease. What is not known is whether H~2~S is efficacious in end stage cardiovascular disease.

Considerable work has also focused on the impact sulfide-based therapies have in ameliorating cardiac ischemia-reperfusion injury. Lefer and colleagues have shown that pretreatment with sodium sulfide (Na~2~S) before cardiac ischemia-reperfusion reduces infarct size and improves overall cardiac function [@bib3; @bib82; @bib83]. There are several proposed mechanisms underlying this protective effect. First, H~2~S up-regulates anti-oxidant response element (ARE) genes by inducing the translocation of Nrf-2 to the nucleus [@bib84]. This increases GSH and expression of antioxidant proteins such as heme oxygenase-1, glutathione S-transferase, and thioredoxin-1 [@bib84]. Second, H~2~S acts through Akt-dependent pro-survival pathways to prevent caspase 3 activation and association of pro-apoptotic proteins to mitochondria that are necessary for mitochondrial permeability pore formation and cytochrome *c* release [@bib85]. The effects of H~2~S on the mitochondrion are likely central to overall cardiomyocyte protection [@bib86], which may also involve activation of *K*~ATP~ channels [@bib87]. While some groups attribute the cytoprotection to mitochondrial *K*~ATP~ channels, others using organelle-specific *K*~ATP~ channel blockers show that cytoprotection is due to effects on sarcolemmal channels [@bib88].

Interestingly, daily H~2~S administration for several months prevented perivascular fibrosis and subsequent arteriole occlusion in spontaneously hypertensive rats. [@bib89], suggesting that H~2~S administration may prevent pathogenic vascular remodeling. H~2~S prevents thickening of damaged arterial intima and medial thickening of intramyocardial coronary arterioles [@bib90]. Finally, H~2~S induces neovascularization in models of chronic ischemia [@bib64]. This molecular action of H~2~S may be highly important following acute cardiac ischemia, as maintenance of a highly vascularized myocardium is required for proper organ function. These select findings, when taken together, demonstrate the promise of H~2~S as a treatment for chronic cardiovascular diseases, as well as, in the emergency room for patients suffering from cardiac arrest.

12. Summary {#s0060}
===========

The actions of H~2~S described in this review highlight its ability to function in redox biology and cell signaling. With a *pK*~*a*~ of 6.9, both protonated and anion forms of H~2~S are present at physiological pH. This allows for the free diffusion of H~2~S to all cellular compartments. Because H~2~S-producing enzymes play a diverse role in the larger sulfur cycle of the cell, the production of H~2~S is dependent on cellular redox status. During conditions of oxidative stress the amount of reduced substrates like cysteine available for H~2~S production may be limited. Moreover, steady state H~2~S concentrations will be determined by H~2~S consumption pathways that are redox sensitive as well. Importantly, O~2~ being an antagonist of H~2~S will also accelerate H~2~S oxidation and inhalation of 100% O~2~ is, in fact, a treatment for H~2~S gas inhalation. Also highlighted herein, is the impact of O~2~ tension on the biological actions and outcomes of H~2~S. For example, H~2~S-mediated vasodilation is observed at physiological O~2~ concentrations, whereas at vasoconstriction occurs at hyperoxia ([Fig. 4](#f0020){ref-type="fig"}). These same patterns can also be extended to other biological processes such as inflammation and angiogenesis ([Fig. 4](#f0020){ref-type="fig"}). Furthermore, many of the cytoprotective actions of H~2~S are triggered by and act to attenuate oxidative stress as exemplified by the ability of H~2~S to induce the expression of antioxidant enzymes during myocardial ischemia-reperfusion. In conclusion, investigation of the redox biology of H~2~S will not only increase understanding of its role in human physiology, but its potential therapeutic role in pathologies where oxidative stress is central to the disease process.
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![The enzymatic production of H~2~S. The two primary enzymes responsible for H~2~S production, cystathionine-γ-lyase (CGL) and cystathionine-β-synthase (CBS), are found in the cytosol. CBS catalyzes the first step in H~2~S production through the transsulfuration of homocysteine to cystathionine. CGL in an elimination reaction catalyzes the formation of cysteine and α-ketobutyrate. Cysteine is the substrate from which H~2~S is directly produced either through elimination (CGL) or β-replacement (CBS). Cysteine amino transferase (CAT) catalyzes the formation of 3-mercaptopyruvate, a substrate for the mitochondrial enzyme 3-mercaptopyruvate-*S*-transferase (3-MST). 3-MST can directly produce H~2~S, albeit at lower levels than CBS and CGL, in mitochondria.](gr1){#f0005}

![Proposed pathways of H~2~S removal in mammalian cells. The physiological steady-state concentration of H~2~S *in vivo* is believed to be maintained in the sub-micromolar range. This steady state concentration is established by the production pathways shown in [Fig. 1](#f0005){ref-type="fig"} and the proposed consumption pathways shown within this figure. H~2~S will react non-enzymatically with many biomolecules such as reactive oxygen and nitrogen species, electrophilic lipids like 4-hydroxy-2-nonenal, free heme, and disulfide bonds to form a thiol and perthiol. The catabolism of H~2~S can also be catalyzed enzymatically by the sulfide quinone oxido-reductase system (SQR) comprised by sulfur dioxygenase, rhodanese, and sulfur quinone reductase.](gr2){#f0010}

![The oxidation of H~2~S by the sulfide quinone oxido-reductase system in mitochondria. H~2~S reduces the disulfide composed of the vicinal thiols on the sulfide quinone reductase (SQR) forming a thiol and a perthiol. The second sulfur atom on the perthiol, the sulfane sulfur (S^0^), is the substrate for both the sulfur transferase enzyme, rhodanese, and the sulfur dioxygenase enzyme encoded by the gene ETHE1. Rhodanese catalyzes the formation of thiosulfate (S~2~O~3~^−2^) from sulfite (SO~3~^−2^) and S^0^. ETHE1 catalyzes the formation of SO~3~^−2^. The reduced SQR can then transfer electrons into the ubiquinone (Q) pool, thus coupling the oxidation of H~2~S to electron transfer, H^+^ pumping, and ultimately ATP synthesis.](gr3){#f0015}

![Interaction of O~2~ and H~2~S on physiological outcomes. H~2~S plays a role in many physiological processes. Additionally, it is capable of acting as a therapeutic agent. The concentration of H~2~S, whether endogenously produced or exogenously administered, will dictate the outcome. This can be beneficial at low and intermediate concentrations or harmful at high concentrations. High O~2~ can reverse many of the beneficial roles of H~2~S seen at lower O~2~ concentrations, resulting in, for example, vasoconstriction rather than vasodilation. Additionally, under hypoxic and normoxic conditions, H~2~S promotes angiogenesis. However, at higher concentrations of both O~2~ and H~2~S, an inhibition of cellular proliferation is seen. H~2~S has a narrow therapeutic window within which it is cytoprotective. At high concentrations it can be pro-apoptotic and pro-inflammatory. Finally, the larger doses of H~2~S necessary to induce a hypometabolic effect, can, if pushed further, result in cardiac and respiratory toxicity.](gr4){#f0020}

###### 

Biological and therapeutic actions of H~2~S are O~2~-dependent.

  **Biological context**       **Low O**~**2**~                                                 **High O**~**2**~
  ---------------------------- ---------------------------------------------------------------- ------------------------------------------
  **Inflammation**             Anti-inflammatory: IL-10; ↓ IL-6, ICAM                           Pro-inflammatory: ↑ NF-κB, TNF-α
  **Vasoactivity**             Vasodilatory: ↑ *K*~ATP~ channel conductance                     Vasoconstrictive
  **Angiogenesis**             Pro-angiogenic: VEGF, Hif1-α                                     No effect
  **Respiratory inhibition**   Higher \[H~2~S\] results in more inhibition                      O~2~ acts as an H~2~S antagonist: ↑SO*x*
  **Ischemia-reperfusion**     Ischemic tissue has higher \[H~2~S\]: mito *K*~ATP~, ARE genes   Unknown
